In contrast to the numerous well-known microdeletion syndromes, only a few microduplications have been described, and this discrepancy may be due in part to methodological bias. In order to facilitate the detection of genomic microdeletions and microduplications, we developed a new assay based on QMPSF (Quantitative Multiplex PCR of Short fluorescent Fragments) able to explore simultaneously 12 candidate loci involved in mental retardation (MR) and known to be the target of genomic rearrangements. We first screened 153 patients with MR and facial dysmorphism associated with malformations, or growth anomalies, or familial history, with cytogenetically normal chromosomes, and the absence of FRAXA mutation and subtelomeric rearrangements. In this series, we found a 5q35 deletion removing the NSD1 gene in a patient with severe epilepsy, profound MR and, retrospectively, craniofacial features of Sotos syndrome. In a second series, we screened 140 patients with MR and behaviour disturbance who did not fulfil the de Vries criteria for subtelomeric rearrangements and who had a normal karyotype and no detectable FRAXA mutation. We detected a 22q11 deletion in a patient with moderate MR, obesity, and facial dysmorphism and a 4 Mb 17p11 duplication in a patient with moderate MR, behaviour disturbance, strabismus, and aspecific facial features. This new QMPSF assay can be gradually upgraded to include additional loci involved in newly recognised microduplication/microdeletion syndromes, and should facilitate wide screenings of patients with idiopathic MR and provide better estimates of the microduplication frequency in the MR population.
Introduction
Mental retardation (MR) occurs in 2 -3% of the general population, but its aetiology can be established only in approximately 50% of cases, limiting therefore considerably the efficiency of genetic counselling, detection of carriers, and prenatal diagnosis. 1 In this context, the detection and characterisation of deleterious genomic rearrangements, such as microdeletions and microduplications, represents an important challenge. These rearrangements, resulting mainly from abnormal pairing and nonallelic homologous recombination mediated by repeat elements such as Alu repeats and low-copy repeats (LCRs), are the cause of many Mendelian diseases, contiguous gene syndromes, or chromosomal disorders. 2 -4 Other uncharacterised recombinational hotspots may also key roles, especially in subtelomeric regions where chromosomal rearrangements are found in about 5% of the patients with idiopathic MR. 5 -7 Thus, genome architectural features are involved in the origin of recurrent deleterious DNA rearrangements. 3, 8, 9 The use of FISH has significantly improved the diagnosis of microdeletion syndromes suggested by clinical evidence. Nevertheless, recent descriptions of microduplication syndromes in patients with MR have highlighted the wide phenotypic variability complicating their clinical recognition. Although nonallelic homologous recombination is supposed to generate microdeletions as well as microduplications, in the field of MR only four microduplications have clearly been related to phenotypes: a 15q11 -q13 duplication has been detected in patients presenting autistic features and its frequency has been estimated to 1/200 -600 among patients with developmental delay. 10, 11 A 17p11.2 duplication has been associated with moderate MR and behavioural disturbance. 12, 13 The 22q11 duplication, initially identified in patients with a clinical presentation similar to the classical 22q11 deletion, has recently been shown to result into a highly variable phenotype. 14, 15 A 7q11.23 duplication has been related to severe expressive language delay. 16 Among the possible explanations for the lower frequency of observed duplications, compared to deletions, one can speculate that duplications often result in a different or less severe phenotype and/or that a methodological bias contributes to this discrepancy. Therefore, systematic molecular screenings of patients ascertained independently of the clinical presentation should facilitate the characterisation of the clinical spectrum of microduplications.
CGH-array at a 1 Mb resolution will probably represent in a near future the most attractive tool for genomewide screening to investigate patients with idiopathic MR. Nevertheless, the recent findings highlighting the previously unsuspected extend of the copy-number polymorphisms in the human genome 17 -19 hampers, at the present time, its use on a routine basis in molecular genetics laboratories. 20 -24 Therefore, we considered that molecular assays focused on regions that have already been identified as targets for microdeletions and microduplications should be more effective in detecting selectively deleterious rearrangements. In order to facilitate the detection of microrearrangements and especially duplications in MR patients, we developed a simple assay based on QMPSF (Quantitative Multiplex PCR of Short Fluorescent Fragments), a method in which short genomic sequences are simultaneously amplified under quantitative conditions using dye-labelled primers. QMPSF has been shown to be a sensitive method for the detection of both deletions and duplications 25 -28 and is currently used in numerous molecular diagnostic laboratories. The QMPSF assay that we developed for the present study explores simultaneously 12 candidate loci known to be the target of genomic rearrangements and involved in MR. Here, we report the results obtained on two series of patients with idiopathic MR, the first series consisting of 153 patients referred for subtelomeric rearrangement screening, and the second series consisting of 140 patients referred for fragile X syndrome testing.
Patients and methods

Patients
A total of 293 patients was analysed in this study. For each patient, blood samples were collected after having obtained written informed consent. Each patient had been examined by a clinical geneticist or a experienced pediatrician and had been diagnosed with developmental delay. The study population was divided into two groups: the first series was composed of 153 patients (92 males and 61 females) with MR and facial dysmorphism associated with malformations, or growth anomalies, or familial history. The additional inclusion criteria were cytogenetically normal chromosomes and no detectable subtelomeric rearrangement. In this series, 69 cases (45.5%) presented with a familial history of MR, whereas 83 cases (54%) were sporadic and the familial history of one patient was unknown because of adoption. The second series was composed of 140 consecutive files of patients (104 males and 36 females) with MR and behaviour disturbance referred for Fragile X syndrome testing. These patients did not fulfil the de Vries criteria for subtelomeric rearrangements, exhibited normal chromosomes and did not harbour expansions within the FMR1 gene. 29 In this second series, 35 cases (25%) presented with a familial history of MR, whereas 104 cases (74%) were sporadic and one patient was adopted. Genomic DNA was extracted from peripheral blood lymphocytes using the QIAamp DNA blood mini kit (Qiagen, Courtaboeuf, France).
QMPSF analyses
Short exonic fragments (170 -240 pb) of 12 candidate loci (Table 1) were simultaneously PCR amplified, in a single tube, using dye-labelled primers corresponding to unique sequences ( Table 2 ). An additional fragment, corresponding to exon 13 of the HMBS gene located on chromosome 11, was coamplified, as a control. PCR was performed in a final volume of 25 ml containing 100 ng of genomic DNA, 0.3 -0.9 mM of each primer, 200 mM dNTPs, 1.5 mM MgCl 2 , 10% of DMSO, and 1 U of Taq DNA polymerase (ABgene, Courtaboeuf, France). The PCR consisted of 22 cycles of 941C for 10 s, 521C for 15 s, and 721C for 20 s, preceded by an initial denaturation step of 5 min at 941C and followed by a final extension of 5 min at 721C. One ml of the PCR product was resuspended in a mix containing 1.25 ml of deionised formamide, 0.5 ml of GeneScan-500 Rox (PE Applied Biosystems, Foster City, CA, USA), and 1 ml of loading buffer. After denaturation for 3 min at 901C, 2 ml of each sample was loaded on an Applied Biosystems model 3100 automated sequencer (PE Applied Biosystems, Foster City, CA, USA). The data were analysed using the Genescan software (PE Applied Biosystems, Foster City, CA, USA). Electropherograms were superimposed to those generated from a normal control DNA by adjusting to the same level the peaks obtained for the control amplicon and the heights of the corresponding peaks were then compared between the different samples. Abnormal profiles were confirmed with a locus-specific QMPSF. The Sotos QMPSF includes amplicons exploring the 22 coding exons of the NSD1 gene. The DiGeorge QMPSF includes 22 amplicons corresponding to 22 genes 
Results
We developed a molecular assay, based on the QMPSF method, which is suitable for rapid screening of large series of DNA samples for common microdeletion and microduplication syndromes. This new QMPSF assay includes 12 exonic amplicons, each corresponding to a distinct locus involved in MR ( (Table 2) . Moreover, we have previously designed several locus-specific QMPSF assays, described in Patients and methods that can be used for more detailed analysis of most of the regions included in this new QMPSF assay.
We first validated this QMPSF assay by using positive controls consisting of DNA samples from patients presenting with either Williams -Beuren, Smith -Magenis, Sotos, DiGeorge, 22q11 duplication, Prader -Willi, or cri-du-chat syndromes and harbouring, in each case, a heterozygous deletion or duplication of the corresponding gene. As shown in Table 3 , in QMPSF analysis, heterozygous deletions can easily be detected by a 0.5 reduction of the peak heights whereas duplications result in a 1.5 increase.
We then screened 293 patients with MR. In the first series, we analysed 153 patients referred for subtelomeric testing, presenting with clinical criteria suggestive of the Table 3 Validation of the microdeletion/microduplication QMPSF assay using positive controls consisting of DNA samples from patients presenting with either Williams -Beuren (WBS), Smith -Magenis (SMS), Sotos, DiGeorge (DGS), 22q11 duplication (22dup), Prader -Willi (PWS), or cri-du-chat syndromes. Bold values correspond to the detection of either a microdeletion or a microduplication using the amplicon within the gene of interest for each positive control The copy-number change for each locus has been calculated using the peak height H of each locus-specific peak (see Figures 1a, 2a and 3a ) normalised to the peak heights H HMBS of the HMBS control (C in Figures 1a, 2a and 3a) . presence of a chromosomal abnormality, without detectable subtelomeric rearrangements. The QMPSF profiles revealed, in one patient, a 50% reduction of the peak corresponding to the NSD1 amplicon (Figure 1a ). Subsequent QMPSF analysis, specific of the NSD1 locus, confirmed the existence of a 5q35 heterozygous deletion removing all the coding exons of the NSD1 gene (Figure 1b) and suggested the diagnosis of Sotos syndrome in this patient, who presented with profound MR in the context of generalised seizures. He was the first child of unrelated parents, born at term after an uneventful pregnancy with normal mensurations and developed West syndrome at 3 months of age. At 12 years of age, he presented with profound MR (he could not walk and talk), macrocephaly with head circumference above the 98th centile, normal height, a long and narrow face with pointed chin. Cerebral resonance magnetic imaging showed slight dilatation of cerebral ventricules.
In the second series, we screened 140 patients with MR and behaviour disturbance referred for Fragile X syndrome testing. In one patient, the QMPSF profile revealed a heterozygous deletion of the TBX1 amplicon exploring the 22q11 region (Figure 2a) . A 22q11 locus QMPSF analysis 30 showed that this patient harbour the classical 3 Mb 22q11 deletion associated with DiGeorge syndrome (Figures 2b  and c) , and this rearrangement was confirmed by FISH (Figure 2c) . These results led to the diagnosis of a 22q11 deletion syndrome in this 25-year-old man who presented with moderate developmental delay, seizures, overweight stature, and facial dysmorphism including a bulbous nose and short palpebral fissures. He spoke correctly but his voice sounded mildly nasal. His IQ was estimated at 46 and he presented behaviour disturbance such as tantrums. Cardiac and renal ultrasonographies revealed no malformation.
In the same series, the QMPSF assay revealed a 1.5 increase of the peak corresponding to the RAI1 amplicon (Figure 3a) . Subsequent QMPSF analyses in this patient, using a QMPSF specific of the 17p11 locus, confirmed the 17p11 duplication and allowed us to estimate to 4 Mb the size of the duplicated segment (Figures 3b and c) . This rearrangement was confirmed by FISH (Figure 3c ). We identified this 17p11 duplication in a 5-year-old boy presenting with MR, mild facial dysmorphic features and behaviour disturbance. He was born after an uneventful pregnancy. Caesarean section was performed at full term for nonprogression of the labour. Clinical examination and mensurations at birth were normal. He was the first child of young and nonconsanguineous parents. Family history was unremarkable. As an infant, he was described as very calm and not interested by social activities. He was able to sit after the age of 1 year and could walk unaided at 18 months of age. First words appeared after the age of 3 years. Between 3 and 4 years, moderate behaviour disturbance (attention deficit, agitation, frustration intolerance) was noted. No sleep disturbance was noticed. At the age of 5 years and 8 months, he presented with normal physical examination, normal growth, and normal neurological examination. Social interaction was good, but language was severely impaired. Mild facial dysmorphic features included high and wide forehead, moderate hypertelorism, thin upper lip, short philtrum and divergent strabismus (Figure 3e ). Cerebral RMN was normal. IQ evaluation was impossible because of behavioural disturbance. In order to provide genetic counselling within this family, parents were tested by QMPSF and FISH since the latter method is the only one which can detect balanced rearrangements, whereas QMPSF had a higher sensitivity than FISH to detect duplications. These analyses show that the parents did not harbour the 17p11 duplication or a balanced translocation, suggesting a de novo occurrence.
Discussion
In order to facilitate systematic molecular screenings of MR patients for microrearrangements, we developed a new assay based on the QMPSF method and focused on 12 genomic regions involved in MR and corresponding to Alu/ LCRs-mediated rearrangements or subtelomeric imbalances (Table 1) . Using this microdeletion/microduplication QMPSF, we screened 293 patients with developmental delay and we identified three genomic rearrangements: a NSD1 deletion leading subsequently to the diagnosis of Sotos syndrome, a 22q11 deletion and a 17p11 duplication (Figures 1, 2 and 3) . It is noteworthy that, like in our case, the eight 17p11 duplications reported so far have been identified in the course of wide chromosomal screenings of MR patients. 12, 32 The clinical features of these eight Each of the genomic imbalances that we found in this study was confirmed by an independent locus-specific QMPSF, which also allowed us to determine the boundaries of the rearrangement (Figures 1b, 2b and 3b) . We estimated the size of the 17p11 duplication to 4 Mb by a locus-specific QMPSF indicating that this rearrangement, like previously reported cases, 12, 37 can be considered as the reciprocal event of the common 4 Mb SMS deletion. (Figure 3b and c) . Furthermore, the FISH assay proved the tandem position of the duplicated segment (Figure 3d) . The SMS deletions, as well as reciprocal duplications flanked by the proximal and distal LCRs termed SMS-REP, have been shown to result from unequal crossing-over events with no parental origin bias. 38 In conclusion, the microdeletion/microduplication QMPSF assay represents a powerful tool for rapid screening for microdeletions and microduplications at several candidate loci in large series of MR patients. We think that its simplicity, reproducibility, and throughput fit the requirements of medical molecular genetics laboratories. Furthermore, the flexibility of the QMPSF method will allow the gradual integration of new candidate loci recognised as deleted or duplicated in MR. This flexibility also considerably facilitates, in each patient harbouring a rearrangement, the delineation of the boundaries. The systematic screening of patients with idiopathic MR, using this type of assay, should facilitate the estimation of microduplications frequency in the MR population and the characterisation of the microduplications related phenotype.
